CD151 Gene and Protein Expression Provides Independent Prognostic Information for Patients with Adenocarcinoma of the Esophagus and Gastroesophageal Junction Treated by Esophagectomy
- 246 Downloads
Esophageal and gastroesophageal junctional (GEJ) adenocarcinoma is one of the most fatal cancers and has the fastest rising incidence rate of all cancers. Identification of biomarkers is needed to tailor treatments to each patient’s tumor biology and prognosis.
Gene expression profiling was performed in a test cohort of 80 chemoradiotherapy (CRTx)-naïve patients with external validation in a separate cohort of 62 CRTx-naïve patients and 169 patients with advanced-stage disease treated with CRTx.
As a novel prognostic biomarker after external validation, CD151 showed promise. Patients exhibiting high levels of CD151 (≥median) had a longer median overall survival than patients with low CD151 tumor levels (median not reached vs. 30.9 months; p = 0.01). This effect persisted in a multivariable Cox-regression model with adjustment for tumor stage [adjusted hazard ratio (aHR), 0.33; 95 % confidence interval (CI), 0.14–0.78; p = 0.01] and was further corroborated through immunohistochemical analysis (aHR, 0.22; 95 % CI, 0.08–0.59; p = 0.003). This effect was not found in the separate cohort of CRTx-exposed patients.
Tumoral expression levels of CD151 may provide independent prognostic information not gained by conventional staging of patients with esophageal and GEJ adenocarcinoma treated by esophagectomy alone.
KeywordsGene Expression Omnibus Validation Cohort Multimodality Therapy Resection Margin Status CD151 Protein Expression
Oliver M. Fisher is supported by the Australian National Health & Medical Research Council (NHMRC; GNT1094423) and the Swiss National Science Foundation (P1SKP3_161806). David C. Whiteman is supported by a Research Fellowship (APP1058522) from the NHMRC. The Australian Cancer Study was supported by NHMRC Program Grants (#552429). PROBENET was supported by an NHMRC Centre of Research Excellence Grant (APP1040947) and this study was supported in part by Darryl and Ann Courtney O’Connor through the Curran Foundation of St. Vincent’s Hospital.
None to declare.
- 10.Peters CJ, Rees JR, Hardwick RH, et al. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology. 2010;139:1995–2004 e15.Google Scholar
- 18.Fisher OM, Levert-Mignon AJ, Lord SJ, et al. Cathepsin E is a novel highly overexpressed biomarker in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2014;146(Suppl 1):S-1–S-1099.Google Scholar
- 23.R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna; 2013.Google Scholar